Chemicals
Showing 8551–8700 of 41137 results
-
AG-1557 is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase with a pIC50 value of 8.194.{32831}
Brand:CaymanSKU:-Available on backorder
AG-1557 is an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase with a pIC50 value of 8.194.{32831}
Brand:CaymanSKU:-Available on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of protein tyrosine kinases. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010248 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of protein tyrosine kinases. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010248 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of protein tyrosine kinases. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010248 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of protein tyrosine kinases. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010248 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010300 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010300 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010300 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as protein tryrosine kinase blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010300 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-183 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 0.8 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010315 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-183 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 0.8 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010315 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-183 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 0.8 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010315 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-183 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 0.8 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010315 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-213 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 2.4 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010314 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-213 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 2.4 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010314 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-213 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 2.4 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010314 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-213 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 2.4 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010314 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF) by blocking the phosphorylation of specific tyrosine residues.{14963} AG-370 is a selective inhibitor of PDGF receptor kinase with an IC50 value of 20 µM in human bone marrow fibroblasts. It displays comparatively weak inhibition of the EGF receptor (IC50 = 820 µM).{16600,850,16601}
Brand:CaymanSKU:10010568 - 1 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF) by blocking the phosphorylation of specific tyrosine residues.{14963} AG-370 is a selective inhibitor of PDGF receptor kinase with an IC50 value of 20 µM in human bone marrow fibroblasts. It displays comparatively weak inhibition of the EGF receptor (IC50 = 820 µM).{16600,850,16601}
Brand:CaymanSKU:10010568 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF) by blocking the phosphorylation of specific tyrosine residues.{14963} AG-370 is a selective inhibitor of PDGF receptor kinase with an IC50 value of 20 µM in human bone marrow fibroblasts. It displays comparatively weak inhibition of the EGF receptor (IC50 = 820 µM).{16600,850,16601}
Brand:CaymanSKU:10010568 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF) by blocking the phosphorylation of specific tyrosine residues.{14963} AG-370 is a selective inhibitor of PDGF receptor kinase with an IC50 value of 20 µM in human bone marrow fibroblasts. It displays comparatively weak inhibition of the EGF receptor (IC50 = 820 µM).{16600,850,16601}
Brand:CaymanSKU:10010568 - 5 mgAvailable on backorder
Protein tyrosine kinase (Ptk) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of Ptks. Tyrphostins are a class of antiproliferative compounds which act as Ptk blockers.{14963} Leukemic cells from patients in relapse have constitutively activated JAK2 Ptk. AG-490 is an inhibitor of JAK2 activity and selectively blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 almost completely blocks growth of all pre-B acute leukemia (ALL) cells at a concentration of 5 µM.{2158} Furthermore, inhibition of JAK/STAT signaling in satellite cells via AG-490 and the STAT3 inhibitor 5,15-DPP (Item No. 16090) has been used to stimulate muscle regeneration in a model of aging skeletal muscle deterioration.{27730}
Brand:CaymanSKU:10010311 - 10 mgAvailable on backorder
Protein tyrosine kinase (Ptk) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of Ptks. Tyrphostins are a class of antiproliferative compounds which act as Ptk blockers.{14963} Leukemic cells from patients in relapse have constitutively activated JAK2 Ptk. AG-490 is an inhibitor of JAK2 activity and selectively blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 almost completely blocks growth of all pre-B acute leukemia (ALL) cells at a concentration of 5 µM.{2158} Furthermore, inhibition of JAK/STAT signaling in satellite cells via AG-490 and the STAT3 inhibitor 5,15-DPP (Item No. 16090) has been used to stimulate muscle regeneration in a model of aging skeletal muscle deterioration.{27730}
Brand:CaymanSKU:10010311 - 25 mgAvailable on backorder
Protein tyrosine kinase (Ptk) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of Ptks. Tyrphostins are a class of antiproliferative compounds which act as Ptk blockers.{14963} Leukemic cells from patients in relapse have constitutively activated JAK2 Ptk. AG-490 is an inhibitor of JAK2 activity and selectively blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 almost completely blocks growth of all pre-B acute leukemia (ALL) cells at a concentration of 5 µM.{2158} Furthermore, inhibition of JAK/STAT signaling in satellite cells via AG-490 and the STAT3 inhibitor 5,15-DPP (Item No. 16090) has been used to stimulate muscle regeneration in a model of aging skeletal muscle deterioration.{27730}
Brand:CaymanSKU:10010311 - 5 mgAvailable on backorder
Protein tyrosine kinase (Ptk) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of Ptks. Tyrphostins are a class of antiproliferative compounds which act as Ptk blockers.{14963} Leukemic cells from patients in relapse have constitutively activated JAK2 Ptk. AG-490 is an inhibitor of JAK2 activity and selectively blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 almost completely blocks growth of all pre-B acute leukemia (ALL) cells at a concentration of 5 µM.{2158} Furthermore, inhibition of JAK/STAT signaling in satellite cells via AG-490 and the STAT3 inhibitor 5,15-DPP (Item No. 16090) has been used to stimulate muscle regeneration in a model of aging skeletal muscle deterioration.{27730}
Brand:CaymanSKU:10010311 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative, compounds that act as PTK blockers. PTK inhibitors that preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-494 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 1 µM in HT-22 cells.{14964}
Brand:CaymanSKU:10010242 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative, compounds that act as PTK blockers. PTK inhibitors that preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-494 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 1 µM in HT-22 cells.{14964}
Brand:CaymanSKU:10010242 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative, compounds that act as PTK blockers. PTK inhibitors that preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-494 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 1 µM in HT-22 cells.{14964}
Brand:CaymanSKU:10010242 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative, compounds that act as PTK blockers. PTK inhibitors that preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-494 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 1 µM in HT-22 cells.{14964}
Brand:CaymanSKU:10010242 - 50 mgAvailable on backorder
AG-528 is a tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 μM, respectively, for inhibition of autophosphorylation).{45071} It also inhibits pantothenate kinase 3 (PanK3; IC50 = 3 μM).{46757} AG-528 inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 μM).{45071}
Brand:CaymanSKU:29666 - 10 mgAvailable on backorder
AG-528 is a tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 μM, respectively, for inhibition of autophosphorylation).{45071} It also inhibits pantothenate kinase 3 (PanK3; IC50 = 3 μM).{46757} AG-528 inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 μM).{45071}
Brand:CaymanSKU:29666 - 100 mgAvailable on backorder
AG-528 is a tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 μM, respectively, for inhibition of autophosphorylation).{45071} It also inhibits pantothenate kinase 3 (PanK3; IC50 = 3 μM).{46757} AG-528 inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 μM).{45071}
Brand:CaymanSKU:29666 - 250 mgAvailable on backorder
AG-528 is a tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 μM, respectively, for inhibition of autophosphorylation).{45071} It also inhibits pantothenate kinase 3 (PanK3; IC50 = 3 μM).{46757} AG-528 inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 μM).{45071}
Brand:CaymanSKU:29666 - 50 mgAvailable on backorder
AG-555 is a tyrphostin inhibitor of the EGF receptor (EGFR; IC50 = 0.7 μM).{45071} It selectively inhibits EFGR over ErbB2 (IC50 = 35 μM). AG-555 inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 μM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis when used at concentrations ranging from 1 to 50 μM.{45071,45072} It also inhibits Moloney murine leukemia virus (Mo-MuLV) reverse transcriptase activity (IC50 = 10.8 μM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 μM).{45073}
Brand:CaymanSKU:23247 - 10 mgAvailable on backorder
AG-555 is a tyrphostin inhibitor of the EGF receptor (EGFR; IC50 = 0.7 μM).{45071} It selectively inhibits EFGR over ErbB2 (IC50 = 35 μM). AG-555 inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 μM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis when used at concentrations ranging from 1 to 50 μM.{45071,45072} It also inhibits Moloney murine leukemia virus (Mo-MuLV) reverse transcriptase activity (IC50 = 10.8 μM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 μM).{45073}
Brand:CaymanSKU:23247 - 25 mgAvailable on backorder
AG-555 is a tyrphostin inhibitor of the EGF receptor (EGFR; IC50 = 0.7 μM).{45071} It selectively inhibits EFGR over ErbB2 (IC50 = 35 μM). AG-555 inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 μM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis when used at concentrations ranging from 1 to 50 μM.{45071,45072} It also inhibits Moloney murine leukemia virus (Mo-MuLV) reverse transcriptase activity (IC50 = 10.8 μM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 μM).{45073}
Brand:CaymanSKU:23247 - 5 mgAvailable on backorder
AG-555 is a tyrphostin inhibitor of the EGF receptor (EGFR; IC50 = 0.7 μM).{45071} It selectively inhibits EFGR over ErbB2 (IC50 = 35 μM). AG-555 inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 μM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis when used at concentrations ranging from 1 to 50 μM.{45071,45072} It also inhibits Moloney murine leukemia virus (Mo-MuLV) reverse transcriptase activity (IC50 = 10.8 μM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 μM).{45073}
Brand:CaymanSKU:23247 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-82 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 3 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010312 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-82 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 3 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010312 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-82 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 3 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010312 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds that act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-82 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 3 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010312 - 50 mgAvailable on backorder
The HER2/Neu proto-oncogene is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK) which includes EGFR, HER2/Neu, HER3 and HER4.{15161} Overexpression of HER2/Neu occurs in 25-30% of human breast and ovarian cancer. AG-825 is a selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/Neu. In cell-free assays, AG-825 inhibits Her2/Neu, EGFR, and PDGFR autophosphorylation with IC50 values of 0.35, 19, and 40 µM, respectively.{15151} However, in select whole cells, the high concentration of ATP prevents inhibition of kinase activity by AG-825.{15151} Concentrations of 50 µM AG-825, however, consistently inhibit Her2/Neu signalling and promote killing of human LNCaP, C4, and C4-2 prostate cancer cells.{15152}
Brand:CaymanSKU:10010243 - 1 mgAvailable on backorder
The HER2/Neu proto-oncogene is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK) which includes EGFR, HER2/Neu, HER3 and HER4.{15161} Overexpression of HER2/Neu occurs in 25-30% of human breast and ovarian cancer. AG-825 is a selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/Neu. In cell-free assays, AG-825 inhibits Her2/Neu, EGFR, and PDGFR autophosphorylation with IC50 values of 0.35, 19, and 40 µM, respectively.{15151} However, in select whole cells, the high concentration of ATP prevents inhibition of kinase activity by AG-825.{15151} Concentrations of 50 µM AG-825, however, consistently inhibit Her2/Neu signalling and promote killing of human LNCaP, C4, and C4-2 prostate cancer cells.{15152}
Brand:CaymanSKU:10010243 - 10 mgAvailable on backorder
The HER2/Neu proto-oncogene is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK) which includes EGFR, HER2/Neu, HER3 and HER4.{15161} Overexpression of HER2/Neu occurs in 25-30% of human breast and ovarian cancer. AG-825 is a selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/Neu. In cell-free assays, AG-825 inhibits Her2/Neu, EGFR, and PDGFR autophosphorylation with IC50 values of 0.35, 19, and 40 µM, respectively.{15151} However, in select whole cells, the high concentration of ATP prevents inhibition of kinase activity by AG-825.{15151} Concentrations of 50 µM AG-825, however, consistently inhibit Her2/Neu signalling and promote killing of human LNCaP, C4, and C4-2 prostate cancer cells.{15152}
Brand:CaymanSKU:10010243 - 5 mgAvailable on backorder
The HER2/Neu proto-oncogene is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK) which includes EGFR, HER2/Neu, HER3 and HER4.{15161} Overexpression of HER2/Neu occurs in 25-30% of human breast and ovarian cancer. AG-825 is a selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/Neu. In cell-free assays, AG-825 inhibits Her2/Neu, EGFR, and PDGFR autophosphorylation with IC50 values of 0.35, 19, and 40 µM, respectively.{15151} However, in select whole cells, the high concentration of ATP prevents inhibition of kinase activity by AG-825.{15151} Concentrations of 50 µM AG-825, however, consistently inhibit Her2/Neu signalling and promote killing of human LNCaP, C4, and C4-2 prostate cancer cells.{15152}
Brand:CaymanSKU:10010243 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors.{14963} AG-879 is a tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40 μM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 μM), and the VEGF receptor FLK1 (IC50 = ~1 μM).{15153} Additionally, AG-879 inhibits the activation of ETK with an IC50 value of ~5 nM, which blocks tyrosine phosphorylation of PAK1, suppressing Ras transformation of NIH 3T3 fibroblasts.{19455} AG-879 has also been shown to suppress IL-6-induced tyrosine phosphorylation of STAT3 (IC50 = 15 μM) in schwannoma cells.{19454}
Brand:CaymanSKU:10793 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors.{14963} AG-879 is a tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40 μM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 μM), and the VEGF receptor FLK1 (IC50 = ~1 μM).{15153} Additionally, AG-879 inhibits the activation of ETK with an IC50 value of ~5 nM, which blocks tyrosine phosphorylation of PAK1, suppressing Ras transformation of NIH 3T3 fibroblasts.{19455} AG-879 has also been shown to suppress IL-6-induced tyrosine phosphorylation of STAT3 (IC50 = 15 μM) in schwannoma cells.{19454}
Brand:CaymanSKU:10793 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors.{14963} AG-879 is a tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40 μM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 μM), and the VEGF receptor FLK1 (IC50 = ~1 μM).{15153} Additionally, AG-879 inhibits the activation of ETK with an IC50 value of ~5 nM, which blocks tyrosine phosphorylation of PAK1, suppressing Ras transformation of NIH 3T3 fibroblasts.{19455} AG-879 has also been shown to suppress IL-6-induced tyrosine phosphorylation of STAT3 (IC50 = 15 μM) in schwannoma cells.{19454}
Brand:CaymanSKU:10793 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which selectively inhibit PTKs of key growth factors.{14963} AG-879 is a tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40 μM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 μM), and the VEGF receptor FLK1 (IC50 = ~1 μM).{15153} Additionally, AG-879 inhibits the activation of ETK with an IC50 value of ~5 nM, which blocks tyrosine phosphorylation of PAK1, suppressing Ras transformation of NIH 3T3 fibroblasts.{19455} AG-879 has also been shown to suppress IL-6-induced tyrosine phosphorylation of STAT3 (IC50 = 15 μM) in schwannoma cells.{19454}
Brand:CaymanSKU:10793 - 50 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010313 - 10 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010313 - 25 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010313 - 5 mgAvailable on backorder
Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. Tyrphostins are a class of antiproliferative compounds which act as PTK blockers. PTK inhibitors which preferentially inhibit the epidermal growth factor (EGF) receptor kinase block EGF-dependent cell proliferation.{14963} AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431.{14963}
Brand:CaymanSKU:10010313 - 50 mgAvailable on backorder
Tyrphostins are tyrosine phosphorylation inhibitors that act by inhibiting tyrosine kinases.{15153} AG957 is a tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl), as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 µM, respectively, for human proteins).{29184} It also inhibits epidermal growth factor receptor (IC50 = 0.25 µM).{29184} As the constitutively-active 210 kDa Bcr-Abl fusion protein commonly occurs in chronic myelogenous leukemia (CML) cells, AG957 is commonly used to study Bcr-Abl signaling in the CML K562 cell line.{29187,29186} AG957 is also used to study signaling through c-Abl.{29185}
Brand:CaymanSKU:-Out of stock
Tyrphostins are tyrosine phosphorylation inhibitors that act by inhibiting tyrosine kinases.{15153} AG957 is a tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl), as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 µM, respectively, for human proteins).{29184} It also inhibits epidermal growth factor receptor (IC50 = 0.25 µM).{29184} As the constitutively-active 210 kDa Bcr-Abl fusion protein commonly occurs in chronic myelogenous leukemia (CML) cells, AG957 is commonly used to study Bcr-Abl signaling in the CML K562 cell line.{29187,29186} AG957 is also used to study signaling through c-Abl.{29185}
Brand:CaymanSKU:-Out of stock
Tyrphostins are tyrosine phosphorylation inhibitors that act by inhibiting tyrosine kinases.{15153} AG957 is a tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl), as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 µM, respectively, for human proteins).{29184} It also inhibits epidermal growth factor receptor (IC50 = 0.25 µM).{29184} As the constitutively-active 210 kDa Bcr-Abl fusion protein commonly occurs in chronic myelogenous leukemia (CML) cells, AG957 is commonly used to study Bcr-Abl signaling in the CML K562 cell line.{29187,29186} AG957 is also used to study signaling through c-Abl.{29185}
Brand:CaymanSKU:-Out of stock
Agarotetrol is a chromone derivative originally isolated from agarwood, a component of incense and traditional medicines.{53078,53079}
Brand:CaymanSKU:27662 - 1 mgAvailable on backorder
Agarotetrol is a chromone derivative originally isolated from agarwood, a component of incense and traditional medicines.{53078,53079}
Brand:CaymanSKU:27662 - 10 mgAvailable on backorder
Agarotetrol is a chromone derivative originally isolated from agarwood, a component of incense and traditional medicines.{53078,53079}
Brand:CaymanSKU:27662 - 25 mgAvailable on backorder
Agarotetrol is a chromone derivative originally isolated from agarwood, a component of incense and traditional medicines.{53078,53079}
Brand:CaymanSKU:27662 - 5 mgAvailable on backorder
Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD+) and NAD phosphate (NADP+)-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing a-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.{22138} The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).{22135,22156,20681} AGI-5198 is a potent, selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 and 0.16 µM, respectively, but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 μM).{23141} AGI-5198 has been shown to have anti-tumor efficacy in the TS603 glioma cell line and to lower tumor 2‑HG production in HT1080 and U87MG cells with IC50 values of 0.48 and 0.07 µM, respectively.{23140} In R132H-IDH1 glioma xenografts, AGI-5198 (450 mg/kg/day) caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts.{23141} Under conditions of near complete 2-HG inhibition, AGI-5198 can induce demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation.{23141}
Brand:CaymanSKU:- Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD+) and NAD phosphate (NADP+)-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing a-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.{22138} The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).{22135,22156,20681} AGI-5198 is a potent, selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 and 0.16 µM, respectively, but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 μM).{23141} AGI-5198 has been shown to have anti-tumor efficacy in the TS603 glioma cell line and to lower tumor 2‑HG production in HT1080 and U87MG cells with IC50 values of 0.48 and 0.07 µM, respectively.{23140} In R132H-IDH1 glioma xenografts, AGI-5198 (450 mg/kg/day) caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts.{23141} Under conditions of near complete 2-HG inhibition, AGI-5198 can induce demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation.{23141}
Brand:CaymanSKU:- Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD+) and NAD phosphate (NADP+)-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing a-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.{22138} The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).{22135,22156,20681} AGI-5198 is a potent, selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 and 0.16 µM, respectively, but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 μM).{23141} AGI-5198 has been shown to have anti-tumor efficacy in the TS603 glioma cell line and to lower tumor 2‑HG production in HT1080 and U87MG cells with IC50 values of 0.48 and 0.07 µM, respectively.{23140} In R132H-IDH1 glioma xenografts, AGI-5198 (450 mg/kg/day) caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts.{23141} Under conditions of near complete 2-HG inhibition, AGI-5198 can induce demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation.{23141}
Brand:CaymanSKU:- Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD+) and NAD phosphate (NADP+)-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing a-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.{22138} The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).{22135,22156,20681} AGI-5198 is a potent, selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 and 0.16 µM, respectively, but not wild-type IDH1, wild-type IDH2, or IDH2 mutants (IC50s > 100 μM).{23141} AGI-5198 has been shown to have anti-tumor efficacy in the TS603 glioma cell line and to lower tumor 2‑HG production in HT1080 and U87MG cells with IC50 values of 0.48 and 0.07 µM, respectively.{23140} In R132H-IDH1 glioma xenografts, AGI-5198 (450 mg/kg/day) caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts.{23141} Under conditions of near complete 2-HG inhibition, AGI-5198 can induce demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation.{23141}
Brand:CaymanSKU:-
Isocitrate dehydrogenases (IDHs) are NAD+ and NADP+-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing α-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.{22138} The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).{22135,22156,20681} AGI-6780 is a potent, selective inhibitor of mutant IDH2 with an IC50 value of 23 nM.{23425} It binds allosterically at the dimer interface of mutant IDH2-R140Q, inhibiting 2-HG formation in human glioblastoma U87 and TF-1 cells expressing IDH2-R140Q with IC50 values of 11 and 18 nM, respectively.{23425} In primary human acute myelogenous leukemia cells, AGI-6780 suppressed cell growth and induced differentiation of immature blast cells toward macrophage and granulocytic lineages.{23245}
Brand:CaymanSKU:- Isocitrate dehydrogenases (IDHs) are NAD+ and NADP+-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing α-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.{22138} The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).{22135,22156,20681} AGI-6780 is a potent, selective inhibitor of mutant IDH2 with an IC50 value of 23 nM.{23425} It binds allosterically at the dimer interface of mutant IDH2-R140Q, inhibiting 2-HG formation in human glioblastoma U87 and TF-1 cells expressing IDH2-R140Q with IC50 values of 11 and 18 nM, respectively.{23425} In primary human acute myelogenous leukemia cells, AGI-6780 suppressed cell growth and induced differentiation of immature blast cells toward macrophage and granulocytic lineages.{23245}
Brand:CaymanSKU:- Isocitrate dehydrogenases (IDHs) are NAD+ and NADP+-dependent enzymes in the tricarboxylic acid cycle that catalyze oxidative decarboxylation of isocitrate producing α-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.{22138} The most common mutations map to arginine residues in the catalytic pockets of IDH1 (R132) or IDH2 (R140 and R172) and impart new gain of function catalytic activity leading to the NADPH-dependent conversion of 2-OG to 2-hydroxyglutarate (2-HG).{22135,22156,20681} AGI-6780 is a potent, selective inhibitor of mutant IDH2 with an IC50 value of 23 nM.{23425} It binds allosterically at the dimer interface of mutant IDH2-R140Q, inhibiting 2-HG formation in human glioblastoma U87 and TF-1 cells expressing IDH2-R140Q with IC50 values of 11 and 18 nM, respectively.{23425} In primary human acute myelogenous leukemia cells, AGI-6780 suppressed cell growth and induced differentiation of immature blast cells toward macrophage and granulocytic lineages.{23245}
Brand:CaymanSKU:-
Brand:CaymanSKU:26600 - 1 mgAvailable on backorder
Brand:CaymanSKU:26600 - 5 mgAvailable on backorder
Agistatin D is a pyranacetal fungal metabolite that has been found in the soil fungus FH-A 6239.{49004}
Brand:CaymanSKU:29169 - 1 mgAvailable on backorder
Brand:CaymanSKU:29211 - 1 mgAvailable on backorder
Brand:CaymanSKU:29211 - 500 µgAvailable on backorder
Mammalian sirtuin 2 (SIRT2) is a nicotinamide adenine dinucleotide-dependent histone deacetylase (HDAC) with roles in cell cycle progression and tumorigenesis. AGK2 is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495} It rescues dopamine neurons from α-synuclein toxicity in both in vitro and in vivo Parkinson’s disease models, mimicking the effect of siRNA-mediated blockade of SIRT2 expression.{17495} AGK2 may be a useful tool for studying the roles of SIRT2 in neurodegeneration and aging, as well as cell cycle progression and tumorigenesis.
Brand:CaymanSKU:- Mammalian sirtuin 2 (SIRT2) is a nicotinamide adenine dinucleotide-dependent histone deacetylase (HDAC) with roles in cell cycle progression and tumorigenesis. AGK2 is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495} It rescues dopamine neurons from α-synuclein toxicity in both in vitro and in vivo Parkinson’s disease models, mimicking the effect of siRNA-mediated blockade of SIRT2 expression.{17495} AGK2 may be a useful tool for studying the roles of SIRT2 in neurodegeneration and aging, as well as cell cycle progression and tumorigenesis.
Brand:CaymanSKU:- Mammalian sirtuin 2 (SIRT2) is a nicotinamide adenine dinucleotide-dependent histone deacetylase (HDAC) with roles in cell cycle progression and tumorigenesis. AGK2 is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495} It rescues dopamine neurons from α-synuclein toxicity in both in vitro and in vivo Parkinson’s disease models, mimicking the effect of siRNA-mediated blockade of SIRT2 expression.{17495} AGK2 may be a useful tool for studying the roles of SIRT2 in neurodegeneration and aging, as well as cell cycle progression and tumorigenesis.
Brand:CaymanSKU:- Mammalian sirtuin 2 (SIRT2) is a nicotinamide adenine dinucleotide-dependent histone deacetylase (HDAC) with roles in cell cycle progression and tumorigenesis. AGK2 is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495} It rescues dopamine neurons from α-synuclein toxicity in both in vitro and in vivo Parkinson’s disease models, mimicking the effect of siRNA-mediated blockade of SIRT2 expression.{17495} AGK2 may be a useful tool for studying the roles of SIRT2 in neurodegeneration and aging, as well as cell cycle progression and tumorigenesis.
Brand:CaymanSKU:-
AGK2 (Item No. 13145) is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495,16624} AGK7 is an inactive control to be used in experiments with AGK2. It differs from AGK2, structurally, only in the position of nitrogen in the quinoline group.{17495} AGK7 has IC50 values greater than 50 µM on SIRT1 and SIRT2 and greater than 5 µM on SIRT3.{17495}
Brand:CaymanSKU:- AGK2 (Item No. 13145) is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495,16624} AGK7 is an inactive control to be used in experiments with AGK2. It differs from AGK2, structurally, only in the position of nitrogen in the quinoline group.{17495} AGK7 has IC50 values greater than 50 µM on SIRT1 and SIRT2 and greater than 5 µM on SIRT3.{17495}
Brand:CaymanSKU:- AGK2 (Item No. 13145) is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495,16624} AGK7 is an inactive control to be used in experiments with AGK2. It differs from AGK2, structurally, only in the position of nitrogen in the quinoline group.{17495} AGK7 has IC50 values greater than 50 µM on SIRT1 and SIRT2 and greater than 5 µM on SIRT3.{17495}
Brand:CaymanSKU:- AGK2 (Item No. 13145) is a cell-permeable, selective inhibitor of SIRT2 (IC50 = 3.5 μM) that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.{17495,16624} AGK7 is an inactive control to be used in experiments with AGK2. It differs from AGK2, structurally, only in the position of nitrogen in the quinoline group.{17495} AGK7 has IC50 values greater than 50 µM on SIRT1 and SIRT2 and greater than 5 µM on SIRT3.{17495}
Brand:CaymanSKU:-